Аннотация
Пациенты с воспалительными заболеваниями кишечника (ВЗК) – это особая категория лиц, для которых тактика диагно-
стики и лечения часто требует внимания и участия врачей разного профиля, поскольку большинство клинических симпто-
мов неспецифичны для ВЗК и часто могут встречаться при других заболеваниях с воспалительным компонентом, таких как
кишечные инфекции, лекарственно-индуцированный колит и моногенные заболевания. Кроме того, к настоящему времени
непростой задачей как для клиницистов, так и для пациентов остается мониторинг течения ВЗК, поскольку отсутству-
ют верифицированные неинвазивные критерии оценки достижения клинической и эндоскопической ремиссии заболеваний, а
также биомаркеры эффективности проводимой лекарственной терапии. Данный обзор посвящён анализу существующих
подходов оценки биомаркеров при ВЗК, а также выбору их возможных сочетаний с учетом данных о специфичности и чув-
ствительности, для целей прецизионной диагностики и персонализации подходов терапии. Поиск литературных источников
проводился по базам данных Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, CyberLeninka,
РИНЦ.
Annotation
Patients with inflammatory bowel disease (IBD) are a special category of individuals for whome diagnostic and treatment tactics often
require attention and participation of physicians of different specialties, since most clinical symptoms are not specific for IBD and
can often occur in other diseases with an inflammatory component, such as intestinal infections, drug-induced colitis, and monogenic
diseases. In addition, monitoring the course of IBD remains a difficult task for both clinicians and patients, since there are no verified
non-invasive criteria for assessing the achievement of clinical and endoscopic remission of diseases, as well as biomarkers for the
effectiveness of drug therapy. This review is devoted to the analysis of existing approaches to assessing biomarkers in IBD, as well as the
choice of their possible combinations, taking into account data on specificity and sensitivity, for the purposes of precision diagnostics
and personalization of therapeutic approaches. The search for literary sources was conducted using the following databases: Scopus,
Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, CyberLeninka, and RSCI.
Key words: inflammatory bowel diseases; biomarkers; serologic biomarkers; fecal biomarkers; proteomics; precision diagnostics;
personalization; review
Список литературы
Л И Т Е РАТ У РА
1. Клинические рекомендации РФ 2024. Болезнь Крона. 25.08.2024.
https://cr.minzdrav.gov.ru/schema/176_2.
2. Клинические рекомендации РФ 2024. Язвенный колит. 25.08.2024.
https://cr.minzdrav.gov.ru/schema/193_2.
R E F E R E NC E S
1. Clinical guidelines of the Russian Federation. Crohn’s disease.
25.08.2024. Available at: https://cr.minzdrav.gov.ru/schema/176_2.
(in Russian)
2. Clinical guidelines of the Russian Federation. Ulcerative colitis.
25.08.2024. Available at: https://cr.minzdrav.gov.ru/schema/193_2.
(in Russian)
3. Alghoul Z., Yang C., Merlin D. The Current status of molecular
biomarkers for inflammatory bowel disease. Biomedicines.
2022;10(7):1492.
4. Ami D.S., Bangdiwala S.I. , Drossman D.A., Ghoshal U.C., Magnus
S., Tack J. et al Worldwide prevalence and burden of functional
gastrointestinal disorders. Results of Rome Foundation Global
Study Gastroenterology. 2021; 160:99–114.
5. Arai Y., Arihiro S., Matsuura T., Kato T., Matsuoka M., Saruta M. et
al. Prostaglandin E-major urinary metabolite as a reliable surrogate
marker for mucosal inflammation in ulcerative colitis. Inflamm. Bowel
Dis. 2014;20(7):1208-16.
6. Aziz I., Simrén M. The overlap between irritable bowel syndrome
and organic gastrointestinal diseases. The Lancet Gastroenterology &
Hepatology.2021;6(2):139-148.
7. Berndt U., Bartsch S., Philipsen L., Danese S., Wiedenmann B., Dignass
A.U. et al. Proteomic Analysis of the Inflamed Intestinal Mucosa
Reveals Distinctive Immune Response Profiles in Crohn’s Disease
and Ulcerative Colitis. J. Immunol. 2007; 179:295–304.
8. Bernsmeier C., Cavazza A., Fatourou E.M., Theocharidou E., Akintimehin
A., Baumgartner B. et al. Leucocyte ratios are biomarkers
of mortality in patients with acute decompensation of cirrhosis
and acute-on-chronic liver failure. Aliment Pharmacol. Ther. 2020;
52(5):855-65.
9. Boga S., Alkim H., Koksal A.R., Ozagari A..A, Bayram M., Tekin
N.S. et al. Serum ST2 in inflammatory bowel disease: a potential biomarker
for disease activity. J. Investig. Med. 2016; 64(5):1016-24.
10. Buisson A., Vazeille E., Minet-Quinard R., Goutte M., Bouvier D.,
Goutorbe F. et al. Fecal matrix metalloprotease-9 and lipocalin-2 as
biomarkers in detecting endoscopic activity in patients with Inflammatory
bowel diseases. J. Clin. Gastroenterol. 2018; 52:e53–e62.
11. Correia C.N., Nalpas N.C., McLoughlin K.E., Browne J.A., Gordon
S.V., MacHugh D.E. et al. Circulating microRNAs as potential biomarkers
of infectious disease. Front. Immunol.2017;8:118.
12. Cuković-Cavka S., Vucelić B., Urek M.C., Brinar M., Turk N. The
role of anti-TNF therapy in ulcerative colitis. Acta Med. Croatica.
2013; 67(2):171-7.
13. Danese S., Vermeire S., D’Haens G., Panés J., Dignass A., Magro F.,
et al. Treat to target versus standard of care for patients with Crohn’s
disease treated with ustekinumab (STARDUST): an open-label, multicentre,
randomised phase 3b trial. Lancet Gastroenterol. Hepatol.
2022; 7(4):294-306.
14. Díaz-Jiménez D., De la Fuente M., Dubois-Camacho K., Landskron
G., Fuentes J., Pérez T., et al. Soluble ST2 is a sensitive clinical marker
of ulcerative colitis evolution. BMC Gastroenterol. 2016; 16(1):103.
15. Dragoni G., Innocenti T., Galli A. Biomarkers of Inflammation in Inflammatory
Bowel Disease: How Long before Abandoning Single-
Marker Approaches? Dig. Dis.2020; 39: 190–203.
16. Furfaro F., Ragaini E., Peyrin-Biroulet L., Danese S. Novel therapies
and approaches to inflammatory bowel disease (IBD). J. Clin.
Med.2022;11(15):4374.
17. Gabay C., Kushner I. Acute-phase proteins and other systemic responses
to inflammation. N. Engl. J. Med.1999; 340:448–54.
18. Hagiwara S.I., Okayasu I., Fujiwara M., Matsuura M., Ohnishi H.,
Ito S. et al. Prostaglandin E-major urinary metabolite as a biomarker
for pediatric ulcerative colitis activity. J. Pediatr. Gastroenterol.
Nutr.2017;64(6):955-961.
19. Hsieh S.Y., Shih T.C., Yeh C.Y., Lin C.J., Chou Y.Y., Lee Y.S. Comparative
proteomic studies on the pathogenesis of human ulcerative
colitis. Proteomics.2006;6(19):5322-5331.
20. Ishida N., Sugiura K., Miyazu T., Tamura S., Suzuki S., Tani S. et al.
Prostaglandin E-Major urinary metabolite predicts relapse in patients
with ulcerative colitis in clinical remission. Clin. Transl. Gastroenterol.
2020; 11(12):e00289.
21. Iskandar H.N., Ciorba M.A. Biomarkers in inflammatory bowel
disease: Current practices and recent advances. Transl. Res. 2012;
159:313–25.
22. Johne B., Fagerhol M.K., Lyberg T., Prydz H., Brandtzaeg P., Naess-
Andresen C.F., Dale, I. Functional and clinical aspects of the myelomonocyte
protein calprotectin. Mol. Pathol.1997; 50:113–23.
23. Kane S.V., Sandborn W.J., Rufo P.A., Zholudev A., Boone J., Lyerly
D. et al. Fecal lactoferrin is a sensitive and specific marker in identifying
intestinal inflammation. Am. J. Gastroenterol.2003;98:1309–14.
24. Kawamoto A., Takenaka K., Hibiya S., Ohtsuka K., Okamoto R.,
Watanabe M. Serum leucine-rich alpha2 glycoprotein: a novel biomarker
for small bowel mucosal activity in Crohn’s disease. Clin.
Gastroenterol. Hepatol. 2022; 20:e1196–e1200.
25. Kawamura T., Yamamura T., Nakamura M., Maeda K., Sawada T.,
Ishikawa E. et al. Accuracy of serum leucine-rich alpha-2 glycoprotein
in evaluating endoscopic disease activity in Crohn’s disease. Inflamm.
Bowel Dis. 2023; 29(2):245-53.
26. Komatsu M., Kobayashi D., Saito K., Furuya D., Yagihashi A., Araake
H. et al. Tumor necrosis factor-alpha in serum of patients with inflammatory
bowel disease as measured by a highly sensitive immuno-
PCR. Clin. Chem. 2001; 47(7):1297-1301.
27. Krzystek-Korpacka M., Kempiński R., Bromke M., Neubauer K.
Biochemical biomarkers of mucosal healing for inflammatory bowel
disease in adults. Diagnostics. 2020; 10:367.
28. Kucharzik T., Stoll R, Lügering N., Domschke W. Circulating antiinflammatory
cytokine IL-10 in patients with inflammatory bowel disease
(IBD). Clin. Exp. Immunol. 1995;100(3):452-6.
29. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of
inflammatory bowel disease. Gastroenterology. 2011; 140:1817-26.
30. Liu D., Saikam V., Skrada K.A., Merlin D., Iyer S.S. Inflammatory
bowel disease biomarkers. Med. Res. Rev. 2022; 42(5):1856-87.
31. Liu F., Lee S.A., Riordan S.M., Zhang L., Zhu L. Global studies of
using fecal biomarkers in predicting relapse in inflammatory bowel
disease. Front. Med. (Lausanne).2020; 7:580803.
32. Lopez R.N., Leach S.T., Lemberg D.A., Duvoisin G., Gearry R.B.,
Da A.S. Fecal biomarkers in inflammatory bowel disease. J. Gastroenterol.
Hepatol. 2017; 32:577–82.
33. Mendoza J.L., Abreu M.T. Biological markers in inflammatory bowel
disease: Practical consideration for clinicians. Gastroentérologie
Clin. Biol. 2009; 33:S158–S173.
34. Mitsuyama K., Tomiyasu N., Takaki K., Masuda J., Yamasaki H., Kuwaki
K., et al. Interleukin-10 in the pathophysiology of inflammatory
bowel disease: increased serum concentrations during the recovery
phase. Mediators Inflamm. 2006; 2006(6):26875.
35. Naka T., Fujimoto M. LRG is a novel inflammatory marker clinically
useful for the evaluation of disease activity in rheumatoid arthritis and
inflammatory bowel disease. Immunol. Med. 2018; 41:62–7.
36. Pascual-Figal D.A., Januzzi J.L. The biology of ST2: the international
ST2 consensus panel. Am. J. Cardiol. 2015; 115,7:3B-7B.
37. Pepys M.B., Hirschfield G.M. C-reactive protein: A critical update. J.
Clin. Investig.2003; 111:1805–12.
38. Perera C., McNeil H.P., Geczy, C.L. S100 Calgranulins in inflammatory
arthritis. Immunol. Cell Biol. 2010; 88:41–9.
39. Peyrin-Biroulet L., Sandborn W., Sands B.E., Reinisch W., Bemelman
W., Bryant R.V. et al. Selecting therapeutic targets in inflammatory
bowel disease (STRIDE): determining therapeutic goals for treat-totarget.
Am. J. Gastroenterol. 2015; 110(9):1324-38.
40. Peyrin-Biroulet L., Gonzalez F., Dubuquoy L., Rousseaux C., Dubuquoy
C., Decourcelle C. et al. Mesenteric fat as a source of C reactive
protein and as a target for bacterial translocation in Crohn’s disease.
Gut. 2012; 61:78–85.
41. Rashid H., Hossain B., Siddiqua T., Kabir M., Noor Z., Ahmed M., et
al. Fecal MicroRNAs as potential biomarkers for screening and diagnosis
of intestinal diseases. Front. Mol. Biosci. 2020; 7:181.
42. Sakurai T., Saruta M. Positioning and usefulness of biomarkers in inflammatory
bowel disease. Digestion.2023;104(1):30-41.
43. Sands B.E. Biomarkers of inflammation in inflammatory bowel disease.
Gastroenterology. 2015; 149(5):1275-85.
44. Saverymuttu S.H., Hodgson H.J., Chadwick V.S., Pepys M.B. Differing
acute phase responses in Crohn’s disease and ulcerative colitis.
КЛИНИЧЕСКАЯ ЛАБОРАТОРНАЯ ДИАГНОСТИКА. 2025; 70(2)
https://doi.org/10.51620/0869-2084-2025-70-2-79-88
EDN: UOVUFD
БИОХИМИЯ
88
Gut.1986; 27:809–13.
45. Schönauen K., Le N., von Arnim U., Schulz C., Malfertheiner P., Link
A. Circulating and fecal microRNAs as biomarkers for inflammatory
bowel diseases. Inflamm. Bowel. Dis. 2018; 24(7):1547-57.
46. Sellin J.H., Shah R.R. The Promise and Pitfalls of Serologic Testing
in Inflammatory Bowel Disease. Gastroenterol. Clin. N. Am. 2012;
41:463–82.
47. Shinzaki S., Matsuoka K., Iijima H., Mizuno S., Serada S., Fujimoto
M. et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of
mucosal healing in ulcerativec. J. Crohn’s Colitis. 2017; 11:84–91.
48. Soufli I., Hablal A., Bessaad S., Amri M., Labsi M., Boussa R.S. et al.
Nitric oxide, neutrophil/lymphocyte, and platelet/lymphocyte ratios
as promising inflammatory biomarkers in complicated crohn’s disease:
outcomes of corticosteroids and anti-TNF-α therapies. Inflammation.
2023; 46(3):1091-1105.
49. Stallhofer J., Friedrich M., Konrad-Zerna A., Wetzke M., Lohse P.,
Glas J. et al. Lipocalin-2 is a disease activity marker in inflammatory
bowel disease regulated by IL-17A, IL-22, and TNF-alpha and
modulated by IL23R genotype status. Inflamm. Bowel Dis. 2015, 21:
2327–40.
50. Starr A.E., Deeke S.A., Ning Z., Chiang C.-K., Zhang X., Mottawea
W. et al. Proteomic analysis of ascending colon biopsies from a paediatric
inflammatory bowel disease inception cohort identifies protein
biomarkers that differentiate Crohn’s disease from UC. Gut. 2017;
66:1573–83.
51. Titz B., Gadaleta R.M., Lo Sasso G., Elamin A., Ekroos K., Ivanov
N.V., Peitsch M.C., Hoeng, J. Proteomics and lipidomics in inflammatory
bowel disease research: from mechanistic insights to biomarker
identification. Int. J. Mol. Sci. 2018; 19:2775.
52. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD:
Useful, magic, or unnecessary toys? Gut. 2006; 55:426.
53. Verstockt S., Verstockt B., Machiels K., Vancamelbeke M., Ferrante
M., Cleynen I. et al. Oncostatin M Is a biomarker of diagnosis, worse
disease prognosis, and therapeutic nonresponse in inflammatory bowel
disease. Inflamm. Bowel Dis. 2021; 27(10):1564-75.
54. Viennois E., Zhao Y., Merlin D. Biomarkers of inflammatory bowel
disease: from classical laboratory tools to personalized medicine. Inflamm.
Bowel Dis. 2015; 21:2467-74.
55. Wan T.M., Iyer D.N., Ng L. Roles of microRNAs as non-invasive
biomarker and therapeutic target in colorectal cancer. Histol. Histopathol.
2020; 35(3):225-37.
56. Wang Y., Li C., Wang W., Wang J., Li J., Qian S. et al. Serum albumin
to globulin ratio is associated with the presence and severity of inflammatory
bowel disease. J. Inflamm. Res. 2022; 15:1907-20.
57. West N.R., Hegazy A.N., Owens B.M.J., Bullers S.J., Linggi B., Buonocore
S. et al. Oncostatin M drives intestinal inflammation and
predicts response to tumor necrosis factor-neutralizing therapy in patients
with inflammatory bowel disease. Nat. Med. 2017; 23:579–89.
58. Wright I., Van J.E. A Roadmap to Successful Clinical Proteomics.
Clin. Chem. 2017; 63: 245–7.
59. Yasutomi E., Inokuchi T., Hiraoka S., Takei K., Igawa S., Yamamoto
S. et al. Leucine-rich alpha-2 glycoprotein as a marker of mucosal
healing in inflammatory bowel disease. Sci. Rep. 2021; 11:11086.
60. Yu Q., Zhang S., Wang H., Zhang Y., Feng T., Chen B. et al. TNFAIP6
is a potential biomarker of disease activity in inflammatory bowel disease.
Biomark. Med. 2016;10(5):473-83.